Measurable residual disease assessed by mass spectrometry in peripheral blood in multiple myeloma in a phase II trial of carfilzomib, lenalidomide, dexamethasone and autologous stem cell transplantation.
Benjamin A DermanAndrew T StefkaKen JiangAmanda McIverTadeusz KubickiJagoda K JasielecAndrzej J JakubowiakPublished in: Blood cancer journal (2021)
Keyphrases
- multiple myeloma
- stem cell transplantation
- peripheral blood
- high dose
- mass spectrometry
- liquid chromatography
- low dose
- bone marrow
- cell therapy
- capillary electrophoresis
- gas chromatography
- open label
- platelet rich plasma
- high performance liquid chromatography
- high resolution
- tandem mass spectrometry
- placebo controlled
- randomized controlled trial
- mesenchymal stem cells
- study protocol